viewShield Therapeutics PLC

Shield Therapeutics encouraged by US interest in iron deficiency treatment


  • Developed a breakthrough iron deficiency drug 

  • Feraccru, known as Accrufer in the States, recently won approval in the US

  • Treatment awarded a broad label to treat iron deficiency in adults, significantly widening its potential audience 

  • Shield has tied up an exclusive deal in China with ASK Pharm


Shield Therapeutics PLC -

Quick facts: Shield Therapeutics PLC

Price: 87.5 GBX

Market: LSE
Market Cap: £102.54 m

Evidence from clinical studies shows it provides long-term treatment for maintaining the body’s iron stores. In our view, these factors provide a solid support for negotiating attractive deal terms. 

Emma Ulker, Proactive Research

What Shield does

Shield Therapeutics PLC (LON:STX) is a specialty pharmaceutical company focused on the development and commercialisation of late-stage pharmaceuticals.

Its lead asset, Feraccru (Accrufer in the States), is an oral treatment for iron deficiency with or without anaemia, which is approved in Europe and the US.

On July 26 the Food & Drug Administration (FDA) awarded the treatment a broad label to treat iron deficiency in adults, addressing a population many times wider than the iron-deficiency anaemia indications included in the submission data.

There are around three times as many patients with iron deficiency than with iron deficiency anaemia. That means the total addressable population could reach up to 40mln in the US, according to Proactive Research’s Emma Ulker.

It is also now positioned to directly challenge the market-leading intravenous (IV) iron therapy following a study that showed Feraccru was at least as efficacious as the standard treatment.

“Shield is therefore clearly on a very strong footing to advance its discussions with commercial partners for Accrufer based on this broad approval as well as a very sound data package,” said Ulker in a recent research note.

The US opportunity alone could be worth in excess of US$1bn, analysts reckon.

In January, Shield signed an exclusive agreement worth up to US$63mln for Feraccru to be sold in China.

The deal with ASK Pharm (Beijing Aosaikang Pharmaceutical), covers China, Hong Kong, Macau and Taiwan and will involve an upfront payment of US$11.4mln and up to US$51.4mln in milestone and royalties.

About Feraccru

The drug has a range of features that help differentiate it from the more established iron treatments including:

• Twice-daily dosing without food providing high iron availability

• Raises haemoglobin and iron levels effectively

• Prolonged therapy maintains Hb levels

• Well tolerated

• Non-inferior to IV iron

How it's doing

In May, Shield said talks to find a partner for the product in the US (where it is known as Accrufer) are ongoing with significant interest from a range of companies.

Sales of Feraccru in Germany and the UK rose during the first quarter of 2020, according to the firm's European partner Norgine, though Shield noted this was before the full impact of the pandemic became clear.

Revenues in 2019 are expected to be £0.7mln.

The group's cash balance at March 31 was £11.3mln with the company’s runway extending currently into the first quarter of 2021.

What the boss says: Tim Watts, chief executive 

"I am reassured that despite the current challenges presented by the global pandemic we continue to operate effectively and there has been little disruption to our commercialisation plans.

"We are encouraged by the continued interest from potential US partners during uncertain times, confident of the pressing need for our product as an effective alternative treatment for iron deficiency, and remain committed to advancing commercial discussions to secure the best deal for shareholders."

What the analyst says 

Proactive Research's Emma Ulker on the prospects for a US deal said; "Accrufer is positioned to command a high market share because of its convenience, favourable clinical evidence and side effect profile. STX is progressing towards an agreement that can unlock this key market, and is in the process of scaling-up production of Accrufer ahead of this event."



Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Shield Therapeutics PLC named herein, including the promotion by the Company of Shield Therapeutics PLC in any Content on the Site, the Company...



Shield's Feraccru likely to command 'high market share and branded pricing'

Capital Network analyst Emma Ulker assesses recent progress made at Shield Therapeutics PLC (LON:STX) with its lead asset Feraccru. The drug's approved and marketed in Europe, with a US approval decision pending for July 27. Feraccru is an oral product absorbed in the gut. It's also...

on 11/5/19

3 min read